Search the site
New data on Bayer’s Xarelto®
Monday 3rd December 2012
Bayer HealthCare announced that new data from the clinical development programme for its oral anticoagulant Xarelto┬« (rivaroxaban) will be presented at the 54th American Society of Haematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA, December 8-11, 2012. These data underscore the benefits of rivaroxaban for patients at risk of dangerous blood clots across multiple venous thromboembolic conditions.
Notable data analyses to be presented at ASH 2012 include:
The pivotal EINSTEIN Clinical Trial Programme comprises three Phase III studies evaluating rivaroxaban alone versus the dual-drug regimen of low molecular weight heparin (LMWH) and vitamin K antagonist (VKA) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE.
Xarelto has been approved as a single-drug solution for the treatment of DVT and PE as well as the prevention of recurrent DVT and PE in adults in a number of countries worldwide including Europe and the US.
About Xarelto┬« (Rivaroxaban)
Rivaroxaban is the most broadly indicated new oral anticoagulant and is marketed under the brand name Xarelto┬«. To date, Xarelto┬« is approved for use in the following venous arterial thromboembolic (VAT) indications:
Whilst licences may differ from country to country, across all indications Xarelto┬« is approved in more than 120 countries.
Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. Xarelto┬« is marketed outside the U.S. by Bayer HealthCare and in the US by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).
Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient.
Responsible use of Xarelto┬« is a high priority for Bayer, and the company has developed a Prescribers Guide for physicians and a Xarelto┬« Patient Card for patients to support best practice.
Have your say...
Reducing catheter-related bloodstream infection in adult patients Hb and WBC in combination to predict the normality of the CBC Clinical development of a new patient-dedicated arterial blood analyser Rivaroxaban demonstrates non-inferiority compared to the standard of care for DVT Direct factor Xa inhibitors for the prevention of venous thromboembolism